Lee et al. (Bendris et al., 2012) demonstrated that CCNA2 expression is elevated in KRAS-mutant GC cell lines and primary tumors, increasing the sensitivity of GC patients to PLK1 inhibitors. This evidence concerns the gene CCNA2 and gastric cancer.